FindTrial
Sign In

Psilocybin therapy

DRUG5 trials

Sponsors

Joshua Woolley, MD, PhD, University of California, San Francisco, Centre Hospitalier Universitaire de Nīmes, University Medical Center Groningen, Psyence Australia Pty Ltd

Conditions

ALS (Amyotrophic Lateral Sclerosis)AddictionAdjustment DisorderAdjustment Disorder With Anxious MoodAlcohol-Related DisordersAnxietyAtypical Parkinson DiseaseBipolar II Disorder

Phase 2

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
CompletedNCT04932434
Joshua Woolley, MD, PhDAnxiety, Depression, Parkinson Disease
Start: 2021-08-15End: 2024-12-31Updated: 2026-09-03
Psilocybin Therapy for Depression in Bipolar II Disorder
Active, not recruitingNCT05065294
University of California, San FranciscoBipolar II Disorder
Start: 2022-01-28End: 2025-07-31Target: 14Updated: 2024-09-25
Psilocybin Therapy for Psychological Distress in Palliative Patients
RecruitingNCT06782724
University Medical Center GroningenALS (Amyotrophic Lateral Sclerosis), Atypical Parkinson Disease, COPD (Chronic Obstructive Pulmonary Disease) +2
Start: 2025-07-01End: 2028-01-01Target: 108Updated: 2026-05-08
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
RecruitingNCT07072728
Psyence Australia Pty LtdAdjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer +8
Start: 2025-10-01End: 2027-07-30Target: 87Updated: 2026-03-03

Unknown Phase

Psilocybin in Alcohol Use Disorder With Comorbid Depression
CompletedNCT06235411
Centre Hospitalier Universitaire de NīmesAddiction, Alcohol-Related Disorders, Depressive Disorder
Start: 2024-02-05End: 2025-01-09Updated: 2025-03-19

Related Papers

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.
2025-04-094 citations